Ensign Peak Advisors Inc Has $2.85 Million Stock Position in AnaptysBio, Inc. (NASDAQ:ANAB)

Ensign Peak Advisors Inc raised its stake in AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 184.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 215,454 shares of the biotechnology company's stock after acquiring an additional 139,699 shares during the quarter. Ensign Peak Advisors Inc owned about 0.71% of AnaptysBio worth $2,853,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. JPMorgan Chase & Co. lifted its position in AnaptysBio by 191.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 33,744 shares of the biotechnology company's stock valued at $1,130,000 after purchasing an additional 22,164 shares during the period. Victory Capital Management Inc. raised its stake in shares of AnaptysBio by 41.0% during the fourth quarter. Victory Capital Management Inc. now owns 334,450 shares of the biotechnology company's stock worth $4,428,000 after buying an additional 97,200 shares during the last quarter. Vanguard Group Inc. lifted its holdings in AnaptysBio by 8.4% in the fourth quarter. Vanguard Group Inc. now owns 1,843,740 shares of the biotechnology company's stock valued at $24,411,000 after buying an additional 143,584 shares during the period. Y Intercept Hong Kong Ltd bought a new position in AnaptysBio in the fourth quarter valued at approximately $311,000. Finally, AlphaQuest LLC boosted its stake in AnaptysBio by 1,891.5% in the fourth quarter. AlphaQuest LLC now owns 4,461 shares of the biotechnology company's stock valued at $59,000 after acquiring an additional 4,237 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on ANAB. Johnson Rice reissued a "buy" rating on shares of AnaptysBio in a research note on Wednesday, March 26th. Guggenheim raised their target price on AnaptysBio from $52.00 to $54.00 and gave the stock a "buy" rating in a report on Tuesday, May 6th. Wells Fargo & Company boosted their target price on AnaptysBio from $40.00 to $51.00 and gave the stock an "overweight" rating in a research report on Thursday, February 13th. HC Wainwright reaffirmed a "neutral" rating and issued a $22.00 price target on shares of AnaptysBio in a research note on Tuesday, March 4th. Finally, Wolfe Research started coverage on shares of AnaptysBio in a research note on Tuesday, February 4th. They set an "outperform" rating and a $25.00 price objective on the stock. Four investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $35.88.

AnaptysBio Stock Down 0.2%

Shares of ANAB traded down $0.05 on Wednesday, hitting $21.06. The company's stock had a trading volume of 53,546 shares, compared to its average volume of 598,302. The firm's fifty day moving average price is $19.11 and its 200-day moving average price is $18.25. AnaptysBio, Inc. has a fifty-two week low of $12.21 and a fifty-two week high of $41.31. The firm has a market capitalization of $618.60 million, a price-to-earnings ratio of -3.46 and a beta of -0.20.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last announced its quarterly earnings results on Monday, May 5th. The biotechnology company reported ($1.28) earnings per share for the quarter, beating analysts' consensus estimates of ($1.30) by $0.02. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. The firm had revenue of $27.77 million for the quarter, compared to analyst estimates of $15.27 million. As a group, equities analysts predict that AnaptysBio, Inc. will post -6.08 earnings per share for the current fiscal year.

AnaptysBio announced that its board has initiated a stock buyback plan on Monday, March 24th that permits the company to repurchase $75.00 million in outstanding shares. This repurchase authorization permits the biotechnology company to reacquire up to 13.1% of its shares through open market purchases. Shares repurchase plans are often a sign that the company's board of directors believes its stock is undervalued.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.